The HD View with Prana Biotechnology, Ltd.

MONDAY, March 18, 2013

Topics that will be focused on are:

• Our therapeutic strategy
• ‘MPAC’ technology, what are these compounds like PBT2?
• Brief historical background as to where our HD program came from.  A bit of science (although without AV this will be brief indeed)
• Why we are hopeful that the mechanism of action may provide patient benefit.  In particular our previous work with PBT2 in AD.
• Outline of Reach2HD, status.